

- DAX1, 401e-1, 401e-1t, 2310  
*DAX1* gene mutations, 435, 2349, 2354t, 2364  
 Day-care centers, 83–84, 83t, 266  
 Daytime sleepiness, 188, 188t, 1726  
*DAZ* gene mutations, 437  
 DBS. *See* Deep brain stimulation (DBS)  
 DBT (dialectical behavior therapy), 2720  
 DCA (dichloroacetate), 102e-13  
*DCC* gene, 538  
 DC-CK1/PARC, 372e-12t  
 DCP (des- $\gamma$ -carboxy prothrombin), 546, 547  
 DC-SIGN, 1216  
 DDAVP. *See* Desmopressin (DDAVP)  
 ddC (zalcitabine), 1276f  
 ddI (didanosine), 1276f, 1278, 1279f, 2023, 2030  
*DDR2* gene mutations, 507t, 509  
 Deafness. *See* Hearing loss  
 Death  
   among international travelers, 793  
   from cancer, 467, 467t, 469f, 470t  
   cardinal signs of, 68–69  
   childhood, 9  
   infectious disease–related, 761, 762f  
   leading causes of, 6e-1  
     age-specific, 30–31t  
     cardiovascular disease, 266e-1, 266e-3, 266e-3f, 266e-3t  
     epidemiologic transition in, 266e-1  
     in men, 7e-1  
     by sex, 6e-1t  
     in United States and Britain, 56t  
     in women, 6e-1t, 6e-2f  
     worldwide, 9, 11t, 266e-2f  
   rates of, by age group, 94e-1f  
   site of, 55–56, 56f  
   of spouse, 69  
   sudden cardiac. *See* Sudden cardiac death  
   sudden natural, 1764  
 Death adders, 2734  
 Death rattle, 68, 69t  
 Death receptors, 102e-8–9, 102e-9f, 102e-10, 372e-23, 372e-26f  
 Debranching enzyme deficiency (type IIIa/b GSD), 433e-2t, 433e-3, 436e-6f, 462e-14  
 DEC. *See* Diethylcarbamazine (DEC)  
 Deception, 17e-1  
 Decerebrate rigidity, 1773–1774  
 Decision analysis, 24, 24f  
 Decision limits, 480e-3  
 Decision-making. *See* Clinical reasoning  
 Dectabine  
   action of, 103e-20  
   adverse effects of, 671  
   for AML, 683  
   for myelodysplasia, 671  
   for sickle cell anemia, 636  
 Declaration of Alma Ata, 13e-1  
 Decompression illness, 477e-4t  
 Decompression sickness, 477e-4t, 477e-7–8, 477e-7t  
 Deconditioning, 47e-1t, 47e-2, 47e-2t  
 Decongestants  
   adverse effects of, 1617t  
   for nasal congestion, 2122, 2123f  
   for otitis media, 230  
   overdosage/poisoning with, 473e-3, 473e-8t  
   for rhinovirus infections, 1203  
   for sinusitis, 227  
   for upper respiratory infections, 226  
 Decorporation, 263e-6  
 Decorticate rigidity, 1773–1774  
 Decremental conduction, 1471  
 Dectin-1, 1342, 1752  
 Decubitus (pressure) ulcers, 830, 1743, 2660  
 Deep brain stimulation (DBS)  
   for depression, 2717  
   for dystonia, 2621  
   for headache, 2596  
   for obsessive-compulsive disorder, 2714  
   for PD, 2616–2617  
 Deep breathing exercises, preoperative, 55  
 Deep neck infections, 235  
 Deep vein thrombosis (DVT), 1631  
   classification of, 1632  
   in critically ill patient, 1734  
   diagnosis of  
     blood tests, 1632  
     clinical decision rules, 1632t  
     clinical evaluation, 1632  
     clinical pearls, 1632  
     imaging algorithms, 1632f, 1634f  
     MRI, 1634  
     venous ultrasonography, 1633, 1633f  
   differential diagnosis of, 1632, 1633t  
   epidemiology of, 743  
   history in, 404–405  
   in HIV infection, 1262  
   paraneoplastic, 612t, 613  
   perioperative prophylaxis of, 55  
   postmenopausal hormone therapy and, 2384t  
   in pregnancy, 47  
   prevention of, 1634, 1636–1637, 1637t, 1734, 1743, 1757–1758, 1785  
   risk factors for, 404–405, 405f  
   treatment of, 1634  
     anticoagulation, 1634–1635, 1635t  
     duration of anticoagulation, 1635–1636  
     inferior vena cava filter, 1636  
     in pregnancy, 47  
 Deepox, 220e-1t  
 Deer tick. *See* *Ixodes* spp. ticks  
 DEET-containing products, 796  
 Defecation, 265, 265f  
 Defecography, 274  
 Defensins, 415  
 Defensive medicine, 20  
 Deferasirox, 639, 1353, 2518  
 Deferoxamine, 473e-11t, 639, 2518  
 Defibrillation, 1769  
 Defibrillator  
   automated external, 1769  
   implantable. *See* Implantable cardioverter-defibrillator (ICD)  
 Deficiency of the IL-1 receptor antagonist (DIRA), 2215  
 Deficiency of the IL-36 receptor antagonist (DITRA), 2215  
 Deformity, joint, 2219t, 2220  
 Degarelix, 585  
 Deglutitive inhibition, 255  
 Dehalogenase 1, 2284t  
 Dehydration  
   in cholera, 1063–1064, 1064t  
   delirium in, 169  
   in diarrhea, 267  
   in hypothermia, 478e-2  
   mechanisms of, 332e-9, 332e-10f  
   in terminally ill patient, 69t  
 Dehydroemetine. *See* Emetine  
 Dehydroepiandrosterone (DHEA)  
   for adrenal insufficiency, 2327  
   adverse effects of, 2130t  
   in hirsutism, 332  
   reference values for, 2759t  
   for SLE, 2130t  
   synthesis of, 2309f  
 Deiodinase(s), 2283f, 2286  
 Déjérine-Roussy syndrome, 161, 2575, 2583  
 Delamanid, 205e-7, 1115, 1119  
 Delavirdine, 1276f, 1278  
 Delayed afterdepolarizations (DADs), 273e-3, 273e-3f  
 Delayed puberty  
   anosmia in, 215, 2380  
   female, 2380–2381, 2381t  
   male, 2361t, 2362–2363  
 Delayed sleep-wake phase disorder, 193  
 Delayed-type hypersensitivity reaction, 372e-29–30, 377–378, 1107  
 Deletion  
   chromosome, 83e-1, 83e-6  
   gene, 432  
 Delirium, 166  
   approach to the patient, 167–170  
   assessment of, 64, 167, 167t  
   clinical features of, 166  
   in critically ill patient, 166, 170, 1735, 1782  
   dementia and, 79, 166  
   diagnosis of, 169–170, 169t  
   drug-induced, 167, 168t, 1606  
   in elderly, 79, 79f, 166  
   epidemiology of, 166  
   etiology of, 64, 168–169, 168t  
   at high altitudes, 476e-5  
   history in, 167  
   pathogenesis of, 166–167  
   physical examination in, 168–169  
   postoperative/ICU, 1735  
   prevention of, 170  
   reversibility of, 166  
   risk factors for, 79, 166  
   in sepsis/septic shock, 1755  
   in terminally ill patient, 64, 64t  
   treatment of, 64–65, 65t, 170, 1782  
 Delirium tremens, 166, 2727, 2728  
 Delta fraction, 280  
 Delta receptors, 468e-1t  
 Deltaretroviruses. *See* Human T-cell lymphotropic virus (HTLV-1)  
 Delusional infestations, 2750–2751  
 Delzicol, 1963  
 Demecarium bromide, 197  
 Demeclocycline  
   adverse effects of, 64e-5, 302  
   for SIADH, 64e-5, 302, 511, 610, 2282  
 Dementia, 170  
   aging and, 94e-1  
   in alcoholism, 2607  
   in ALS/parkinsonian/dementia complex of Guam, 2608  
   aphasia in, 179–180  
   approach to the patient, 171–175  
   in chronic traumatic encephalopathy, 2608  
   clinical features of, 173, 173t  
   in CNS infections, 2607  
   in CNS neoplasms, 2607  
   in CNS vasculitis, 2607  
   in cobalamin deficiency, 2607  
   cognitive examination in, 173–174  
   definition of, 170  
   degenerative  
     Alzheimer's disease. *See* Alzheimer's disease  
     Creutzfeldt-Jakob disease. *See* Creutzfeldt-Jakob disease (CJD)  
     dementia with Lewy bodies. *See* Dementia with Lewy bodies  
     frontotemporal temporal dementia. *See* Frontotemporal dementia (FTD)  
     molecular basis of, 172t  
     types of, 172  
   delirium and, 166  
   diagnosis of, 172t, 174  
   differential diagnosis of, 171t  
   EEG in, 442e-2  
   etiology of, 171, 171t, 2606–2608  
   familial, 451e-2t  
   functional anatomy of, 170  
   history in, 171–172, 172t  
   HIV-associated, 1263, 1264t, 1265f  
   in Huntington's disease, 2606  
   imaging in, 174f, 175f  
   insomnia in, 191  
   intracranial hypotension and, 2607  
   in Korsakoff's syndrome, 2607  
   metal exposure and, 2607–2608  
   multi-infarct, 2602  
   neurologic examination in, 173, 173t  
   in normal-pressure hydrocephalus, 175f, 2606–2607  
   in PD. *See* Parkinson's disease dementia (PDD)  
   in pellagra, 2607  
   physical examination in, 172t, 173  
   postmenopausal hormone therapy and, 2384t, 2385–2386  
   prevalence of, 170  
   in psychiatric diseases, 2608  
   in seizure disorders, 2607  
   semantic, 182  
   in substance abuse, 2608